+1.62%

S&O 500 5,382.45

-0.47%

US 10 400

+2.28%

Nasdaq 16,565.41

+2.28%

Crude Oil 16,565.41

-0.27%

FTSE 100 8,144.87

+1.06%

Gold 2,458.10

-0.53%

Euro 1.09

+0.36%

Pound/Dollar 1.27

Monday, August 3, 2026

Business News

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

by marketdash February 10, 2025

by marketdash February 10, 2025 0 comments

Get New Updates nto Take Care Your Pet

Discover the art of creating a joyful and nurturing environment for your beloved pet.

Will be used in accordance with our Privacy Policy

+1.62%

-0.47%

+2.28%

+2.28%

-0.27%

+1.06%

-0.53%

+0.36%

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

The Importance of Financial Forecasting for Business Planning

Understanding the Basics of Equity Financing for Startups

The Future of Digital Currency: What You Need to Know

Trump Media has moved out 7,000 bitcoin, leaving only likely loan collateral

Earnings call transcript: Latent View meets Q1 2026 estimates, shares fall 5%

Ageas to sell Malaysia JV stake to Maybank for $1.2 billion

Get New Updates nto Take Care Your Pet

Most read

+1.62%

-0.47%

+2.28%

+2.28%

-0.27%

+1.06%

-0.53%

+0.36%

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Trump could make changes to Medicare drug price negotiations

Why We Need a Bipartisan Stablecoin Bill

You may also like

Get New Updates nto Take Care Your Pet

Most read